zealand pharma petrelintide

Zealand Pharma to pay $350M to Roche

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Medical Dialogues · 22h

Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate

Markets Insider · 2d

Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a

Roche And Zealand Team Up To Develop Petrelintide

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

2don MSN

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...

Fierce Biotech2d

Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...

Nasdaq2d

Zealand Pharma, Roche To Co-develop, Co-commercialize Petrelintide And Combination Products

(RTTNews) - Zealand Pharma A/S (ZEAL) announced a global collaboration and license agreement with Roche (RHHBY) to develop petrelintide, Zealand Pharma's amylin analog. The two companies ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results